Shots:

• Skyhawk to receive $40M as upfront and is eligible to receive up to $2.2B as milestones along with royalties on sales. Vertex to get an option to exclusively license WW IP rights to candidates discovered and developed under the collaboration directed at serious diseases
• Following the exercise of its options- Vertex will be responsible for further development and commercialization
• Skyhawk will use its SkySTAR platform to discover & develop novel small molecule therapeutics that modulate RNA splicing targeting the serious disease

­ Ref: PRNewswire | Image: Vertex